TKI De-escalation Safe in Most CML Patients With Major Molecular Response
A de-escalation of tyrosine-kinase inhibitor dose was safe in the majority of patients with chronic myeloid leukemia with stable major molecular response.
Dasatinib Is Safe, Effective in Pediatric Chronic Myeloid Leukemia
Dasatinib was safe and effective in pediatric patients with chronic myeloid leukemia, according to a new study, establishing the agent as a new standard of care for this population.
Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia
This video highlights results of the BFORE trial, which tested bosutinib vs imatinib in newly diagnosed chronic myeloid leukemia patients.
TKI Discontinuation Possible for Some CML Patients
Ahead of the 2017 ASCO Annual Meeting, we discuss the discontinuation of TKIs in some chronic myeloid leukemia patients.
Cytogenetic Abnormalities Do Not Affect Prognosis in Pediatric CML
Chromosomal abnormalities such as a variant t(9;22) translocation do not appear to have significant prognostic impact on children with chronic myeloid leukemia.
Insurance Status Influences Chronic Myeloid Leukemia Survival Outcomes
Insurance status at the time of chronic myeloid leukemia diagnosis appears to have an influence on survival outcomes, with the uninsured and those on Medicaid having worse overall survival.
Challenges in Molecular Monitoring for CML Treatment Response
This video examines the challenge in optimizing and standardizing molecular monitoring for patients with chronic myeloid leukemia.
By clicking Accept, you agree to become a member of the UBM Medica Community.